One-Day Intervention for Depression and Impairment in Migraine Patients (ACT)
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Adults with comorbid depression and migraine will be randomized to a 1-day (6-hour) workshop of Acceptance and Commitment Training + Migraine Education (ACT-ME) or Migraine Education only (MEO). The intervention delivered to both study arms will be identical except for the addition of the ACT component delivered in the ACT-ME condition, thereby allowing an estimate of the specific additive effect of the psychotherapy. Measures of acceptance and behavioral avoidance, theoretically important mechanisms of change, will be used to test intervention components by examining whether these processes are uniquely affected by the ACT-ME intervention and whether they account for observed treatment effects. The central hypothesis is that the ACT-ME treatment will lead to significantly greater reduction in depression (HRSD) and disability (WHO-DAS, WHOQOL, and HDI) at follow-up compared to the MEO treatment. ACT-ME participants also are expected to demonstrate reductions in behavioral avoidance and enhanced acceptance, which mediate treatment effects. Treatment gains are expected to be maintained through the 6-month follow-up.
Aim 1: To examine the efficacy of a 1-day ACT-ME intervention compared to MEO for treating depression in patients with comorbid depression and migraine.
Hypothesis 1: At 3- and 6-month follow-up, ACT-ME will be more efficacious than MEO as assessed by: 1) a significantly greater decline on the Hamilton Rating Scale for Depression (HRSD) total score; 2) a significantly higher proportion of participants showing 50% or greater decline on the HRSD; and 3) a significantly higher proportion of participants no longer meeting depression criteria on SCID-IV.
Aim 2: To examine the efficacy of a 1-day ACT-ME intervention compared to MEO on functioning in patients with comorbid depression and migraine.
Hypothesis 2: At 3- and 6-month follow-up, compared to the MEO group, participants in the ACT-ME group will exhibit significantly greater improvement in functioning (measured by World Health Organization Disability Assessment Schedule-Total Score; WHO-DAS) and quality of life (measured by World Health Organization Quality of Life Total; WHO-QOL), and greater decline in headache-related disability (measured by Headache Disability Inventory; HDI).
Aim 3: To determine whether changes in acceptance-based coping and behavioral avoidance will mediate the changes in depressive symptoms and disability.
Hypothesis 3: Increases in acceptance-based coping and reductions in behavioral avoidance will mediate relations between treatment group and 1) decline in depressive symptoms as measured by the HRSD and 2) disability, as measured by the WHO-DAS and HDI. Acceptance and Behavioral Avoidance will be measured using the Acceptance and Action Questionnaire and Chronic Pain Acceptance Questionnaire.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Carver College of Medicine Department of Psychiatry
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Ages 18-65
- Current major depressive episode on the SCID-IV (46)
- Score of ≥ 17 on the HRSD (47)
- Confirmation of diagnosis of migraine from medical record
- 4-12 migraines in the previous month
Exclusion Criteria:
- Bipolar, psychotic, or current substance use disorders
- History of brain injury
- Imminent suicidality.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ACT-ME
ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping.
It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
|
1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT).
Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc.
The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
Otros nombres:
|
|
Experimental: Migraine Education Only
The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic.
If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement.
However, information on coping practices will be omitted.
|
6 hour discussion of migraine education only (MEO).
This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
HRSD
Periodo de tiempo: 24 weeks
|
The HRSD is a structured clinical interview for depression severity.
Change from baseline measured at 2, 6, 12, and 24 weeks post workshop.
|
24 weeks
|
|
SCID-IV
Periodo de tiempo: 24 weeks
|
Semi-structured clinical interview for depression.
Change from baseline measured at 12 and 24 weeks post workshop.
|
24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
WHO-DAS-II
Periodo de tiempo: 24 weeks
|
This is a self-report questionnaire that measures difficulties due to physical and mental health conditions.
Measure change from baseline at 12 and 24 weeks post-workshop.
|
24 weeks
|
|
WHO-QOL
Periodo de tiempo: 24 weeks
|
The WHO-QOL is a self-report measure that assesses four domains of quality of life: physical health, psychological well-being, social relationships, and environment.
Measure change from baseline at 12 and 24 weeks post workshop.
|
24 weeks
|
|
HDI
Periodo de tiempo: 24 weeks
|
The HDI is a self-report measure that assesses the burden of headaches through perceived impact of headaches on functioning.
Measure changes from baseline at 12 and 24 weeks post workshop.
|
24 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
AAQ-II
Periodo de tiempo: 24 weeks
|
The AAQ-II is a self-report measure that assesses experiential avoidance, or the tendency to avoid unwanted internal experiences (e.g., "I try hard to avoid feeling depressed or anxious"), as well as acceptance, the term used to describe the counter process (e.g., "My thoughts and feelings do not get in the way of how I want to live my life").
Measure changes from baseline at 2, 6, 12, and 24 weeks post workshop.
|
24 weeks
|
|
CPAQ
Periodo de tiempo: 24 weeks
|
The CPAQ is a self-report measure that assesses Activity Engagement, the degree to which one engages in life activities regardless of pain, and Pain Willingness, the willingness to have pain without trying to avoid or reduce it.
Measure change from baseline at 2, 6, 12, and 24 weeks post workshop.
|
24 weeks
|
|
Demographics Questionnaire
Periodo de tiempo: 1 day
|
The following information will be obtained: age, ethnicity, marital status, educational level, household income, occupation, current mental health treatment, current medication, number of migraines in previous month, and age of onset of migraine.
Information will only be obtained at initial meeting.
|
1 day
|
|
Treatment Questionnaire
Periodo de tiempo: 24 weeks
|
Changes in medications and involvement in psychotherapy/counseling will be documented at each contact and will be confirmed by reviewing medical and pharmacy records.
Measured at baseline and 2, 6, 12, and 24 weeks post workshop.
|
24 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 201301712
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre ACT-ME
-
Idorsia Pharmaceuticals Ltd.TerminadoEstudio para investigar la tolerabilidad, seguridad, farmacocinética y farmacodinámica de ACT-389949Sujetos sanosPaíses Bajos
-
Idorsia Pharmaceuticals Ltd.Terminado
-
Idorsia Pharmaceuticals Ltd.Terminado
-
Idorsia Pharmaceuticals Ltd.TerminadoEnfermedad arterial coronaria estableDinamarca, Países Bajos, Singapur, Canadá, Reino Unido, Estados Unidos, Alemania, Suecia
-
Idorsia Pharmaceuticals Ltd.TerminadoFarmacocinética | Farmacodinamia | Tolerabilidad | La seguridadPaíses Bajos
-
University of CoimbraFundação para a Ciência e a TecnologiaDesconocido
-
University of NottinghamDesconocidoSíndrome de estrés del cuidadorReino Unido
-
Azusa Pacific UniversityRetiradoDesórdenes de ansiedad | Trastornos de Estrés, Traumáticos | AnsiedadEstados Unidos
-
Idorsia Pharmaceuticals Ltd.Terminado
-
Aspire Health ScienceDesconocidoNeumonía por COVID-19